Fluconazole potentiated the effect of coumarin anticoagulants may increase in prothrombin time. It promotes the prolongation of the prothrombin time in patients receiving warfarin. Appointing fluconazole in combination with anticoagulants, it is necessary to monitor the prothrombin index.
When concomitantly with fluconazole increased concentration of sulfonylureas – chlorpropamide, glibenclamide, glipizide and tolbutamide, which potentiates the risk of uncontrolled hypoglycemia. It is stanozolol side effects necessary to periodically monitor blood glucose levels and, if necessary, correct the dose of hypoglycemic agents (risk of hypoglycaemia!). Thiazide diuretics : may increase the level of fluconazole in plasma. Phenytoin : concomitant use with fluconazole results in an increase of phenytoin plasma concentrations at clinically relevant degree ( the combined use is necessary monitorirovnie phenytoin plasma concentrations). Rifampicin reduces the following pharmacokinetic parameters of fluconazole a more rapid elimination of fluconazole from plasma (20%) requires an increase in the dose. Cyclosporine A : while receiving fluconazole may increase the concentration of cyclosporine, which requires monitoring of its concentration, control over the performance of the plasma creatinine and dose adjustment.
Theophylline : while receiving with fluconazole may increase theophylline concentration in the blood by increasing its half-life (the risk of intoxication). Requires dynamic clinical monitoring and monitoring of theophylline with a possible correction dosage concentrations. Terfenadine, and cisapride : while receiving fluconazole possible increase in their concentration in the plasma, which is accompanied by a prolongation of the QT interval and potentiates the risk of ventricular arrhythmias including paroxysmal ventricular tachycardia (torsades de . pointes) zidovudine : while receiving fluconazole may increase zidovudine plasma concentrations. rifabutin : when taken with fluconazole may increase the levels of rifabutin plasma, in some cases – the development of uveitis. astemizole : simultaneous reception of astemizole and fluconazole, drugs, metabolism involving a system of enzymes of the cytochrome thestanozolol side effects, can be accompanied by an increase in their concentration in plasma.Tacrolimus : while receiving fluconazole increased risk of nephrotoxicity. at the same time taking fluconazole increases plasma concentration of benzodiazepine short-acting , which in some cases require correction of their doses. The solution for intravenous administration is compatible with 0.9% sodium chloride solution, 5-10% dextrose, Ringer’s solution, potassium chloride solution in glucose solution Hartmann. in view of the likely pharmacological incompatibility does not add or mix Flukomabola solution ® with other drugs ! When assigning the patient a few drugs administered in / in, observe the sequence of administration, or administered Flukomabol ® through separate intravenous catheter or a system / in infusions.
Treatment should be continued until clinical, and immunocompromised patients – also remission. Premature discontinuation of treatment leads to relapse. During treatment it is necessary to monitor blood counts, kidney and liver. In the event of severe impaired renal and hepatic function should stop taking the drug. Hepatotoxic action of Fluconazole is usually reversible, symptoms disappear after cessation of therapy. In the event of skin rash in patients with immunosuppression should be carefully monitored, and if the progression of skin reactions treatment should be discontinued (risk of the syndrome of Stevens-Johnson syndrome, Lyell’s syndrome). Requires monitoring prothrombin index while the use of coumarin anticoagulants. It is recommended to carry out dynamic monitoring of cyclosporine concentrations in the blood in patients after organ transplantation, while receiving , as administration of fluconazole 200 mg / day leads to a slow increase in the concentration of cyclosporine, which can lead to toxic effects.
Taking certain azoles, including fluconazole, can be accompanied by a prolongation of the QT interval, so the appointment in patients at risk of arrhythmias, especially heavy patients, who have organic lesion of the myocardium and the pathways of the heart, electrolyte imbalance and / or receiving supportive kardiotropnyh therapy should be strictly justified and carried out under close medical supervision and monitoring of ECG.
parenteral stanozolol side effects in preterm infants should be undertaken under close medical supervision.
Given dysfunction kidney in elderly (> 65 years) patients, the choice of dose and administration regimen is recommended to take into account the biochemical tests that characterize the function of the kidneys, as well as to conduct their dynamic monitoring.